Welcome to the international HTA database

Showing [23806 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Non-marker based circulating tumour cell capture for solid malignant tumours
2014	Belgian Health Care Knowledge Centre (KCE)	Oncogenetic testing for Lynch syndrome and familial adenomatous polyposis
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of azathioprine in adults: safety
2014	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Intraoperative radiotherapy in colorectal cancer]
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Corus® CAD for obstructive coronary artery disease
2014	Belgian Health Care Knowledge Centre (KCE)	Organisation of care for adults with a rare or complex cancer
2014	Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR)	Innovative medical devices for diabetes management - Update of Short report n. 6/2012
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Negative pressure wound therapy for managing diabetic foot ulcers: a review of the clinical effectiveness, cost-effectiveness, and guidelines
2014	Medical Services Advisory Committee (MSAC)	Cone beam computer tomography (CBCT) for dental/craniofacial imaging
2014	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Review of the indications of stereotactic body radiation therapy (SBRT) in patients with primary tumours and oligometastases]
2014	NIHR Horizon Scanning Centre (NIHR HSC)	RAPIDEC® CARBA NP test for confirmation or detection of Carbapenemase producing bacteria
2014	Belgian Health Care Knowledge Centre (KCE)	Colon cancer: diagnosis, treatment and follow-up
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Virtual reality exposure therapy for adults with post-traumatic stress disorder: a review of the clinical effectiveness
2014	Medical Services Advisory Committee (MSAC)	Oncotype DX® breast cancer assay to quantify the risk of disease recurrence and predict adjuvant hemotherapy benefit
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A13-33 (enzalutamide)]
2014	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Transvaginal mesh in pelvic organ prolapse repair]
2014	NIHR Horizon Scanning Centre (NIHR HSC)	AeriSeal® System for advanced emphysema
2014	Belgian Health Care Knowledge Centre (KCE)	Machine perfusion in kidneys from deceased donors – a rapid assessment – synthesis
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Hyperbaric oxygen therapy for adults with mental illness: a review of the clinical effectiveness
2014	Medical Services Advisory Committee (MSAC)	National Cervical Screening Program renewal
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Indicaterol/glycopyrronium - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	Belgian Health Care Knowledge Centre (KCE)	Informed choice on breast cancer screening: messages to support informed decision
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Normothermia versus therapeutic hypothermia for adult patients after cardiac arrest: clinical evidence
2014	Medical Services Advisory Committee (MSAC)	Radium 223 for the treatment of patients with symptomatic castrate resistant prostate cancer with skeletal metastases
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Afatinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Growth measurement of infants and children: guidelines
2014	Medical Services Advisory Committee (MSAC)	HbA1c test for the diagnosis of diabetes mellitus
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A13-37 (regorafenib)]
2014	NIHR Health Services and Delivery Research programme	Rethinking resistance to 'big IT': a sociological study of why and when healthcare staff do not use nationally mandated information and communication technologies
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Neurofeedback and biofeedback for mood and anxiety disorders: a review of the clinical evidence and guidelines
2014	Medical Services Advisory Committee (MSAC)	Catheter-free ambulatory pH test for Gastroesophageal Reflux Disease (GORD)
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[User testing of IQWiG health information by socially disadvantaged people]
2014	NIHR Health Technology Assessment programme	The clinical and cost-effectiveness of lenalidomide for people who have received at least one prior therapy with bortezomib (partial review of TA171)
2014	NIHR Health Services and Delivery Research programme	Can valid and practical risk-prediction or casemix adjustment models, including adjustment for comorbidity, be generated from English hospital administrative data (Hospital Episode Statistics)? A national observational study
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Admission of patients with suspected or active infection to oncology units: clinical evidence and guidelines
2014	Medical Services Advisory Committee (MSAC)	Remote monitoring of patients with implanted cardiac devices
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ipilimumab (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	NIHR Health Technology Assessment programme	Ipilimumab for previously untreated unresectable malignant melanoma: a single technology appraisal
2014	NIHR Health Services and Delivery Research programme	The design of a survey questionnaire to measure perceptions and behaviour during an influenza pandemic: the Flu TElephone Survey Template (FluTEST).
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Breast reduction surgery for hypermastia: clinical effectiveness and guidelines
2014	Medical Services Advisory Committee (MSAC)	The reduction of mitral regurgitation through tissue approximation using transvenous/transeptal techniques
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A13-35 (dabrafenib)]
2014	NIHR Health Services and Delivery Research programme	Geographical and temporal understanding in place of death in England (1984–2010): analysis of trends and associated factors to improve end-of-life care (GUIDE_Care) – primary research
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Intravenous ketamine for the treatment of mental health disorders: a review of clinical effectiveness and guidelines
2014	Medical Services Advisory Committee (MSAC)	Magnetic Resonance Imaging (MRI) for small bowel and pelvis in Crohn disease
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Arthroscopy of the knee joint for gonarthrosis]
2014	NIHR Health Services and Delivery Research programme	What evidence is there for a relationship between organisational features and patient outcomes in congenital heart disease services? A rapid review
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Endovascular thermal ablation technologies for treatment of varicose veins: a review of clinical effectiveness, safety, cost-effectiveness and guidelines
2014	Medical Services Advisory Committee (MSAC)	Intensive Care Medicine consultation items
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Palliation vs. curation - an attempt to clarify terms]
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Azacitidine (Vidaza) for acute myeloid leukaemia – first line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Wear compliance and donning/doffing of respiratory protection for bioaerosols or infectious agents: a review of the effectiveness, safety, and guidelines
2014	Medical Services Advisory Committee (MSAC)	Palliative care consultation items
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Addendum to Commission A13-44 (ipilimumab, new therapeutic indication)]
2014	National Institute for Health and Care Excellence (NICE)	Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers. NICE medical technologies guidance 20
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Ecorafenib and binimetinib for BRAF V600 mutation-positive melanoma – first and second line
2014	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Neonatal screening for biotinidase deficiency]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Respiratory precautions for protection from bioaerosols or infectious agents: a review of the clinical effectiveness and guidelines
2014	Medical Services Advisory Committee (MSAC)	Review of interim funded service: breast Magnetic Resonance Imaging (MRI)
2014	Haute Autorite de sante (HAS)	[Hip implants]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Trastuzumab emtansine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Ibrutinib (Imbruvica) for newly diagnosed chronic lymphocytic leukaemia – first line
2014	National Evidence-based Healthcare Collaborating Agency (NECA)	[Comparative effectiveness research of computer-assisted navigation in knee arthroplasty]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Motor interventions for autism spectrum disorder in children: clinical effectiveness and guidelines
2014	Medical Services Advisory Committee (MSAC)	IncobotulinumtoxinA (XEOMIN), injection of, for blepharospasm, cervical dystonia (spasmodic torticollis) and post-stroke spasticity of the upper limb
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Radium-223-dichloride - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Niraparib for HER2-negative, germline BRCA mutated, locally advanced or metastatic breast cancer – first or second line
2014	Andalusian Health Technology Assessment Area (AETSA)	[Genetic diseases in Spain: map of genetic tests available in the national health system]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Acetylsalicylic acid for venous thromboembolism prophylaxis: an update of clinical evidence
2014	Medical Services Advisory Committee (MSAC)	RAS (Kirsten RAS and Neuroblastoma RAS) mutation testing for eligibility for panitumumab treatment in previously untreated metastatic colorectal cancer patients.
2014	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Development of composite indicators to measure the quality of prevention and chronic management activities for gynecological cancer screening in primary care]
2014	Haute Autorite de sante (HAS)	[Endobronchial ultrasound-guided transbronchial needle aspiration]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Drug combination of emtricitabine, rilpivirine and tenofovir disoproxil (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Cositecan (Karenitecin) for advanced mucinous epithelial ovarian cancer – second line
2014	Andalusian Health Technology Assessment Area (AETSA)	[Effectiveness, safety and efficiency of palivizumab for prevention of respiratory syncytial virus infection in premature infants]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Oral ginger for the management of chemotherapy-induced nausea and vomiting in pediatric patients: clinical effectiveness and safety
2014	Medical Services Advisory Committee (MSAC)	Resubmission Cetuximab and RAS testing under MBS 73330
2014	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[EndoBarrier® evaluation device for the treatment of morbid obesity with or without diabetes mellitus type II]
2014	Haute Autorite de sante (HAS)	[Assessment of real-time optical endomicroscopy performed during mapping of Barrett's esophagus (BE) (for diagnosis of BE-associated early neoplasia)]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Macitentan - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Mogamulizumab for adult T-cell leukaemia/lymphoma – second and subsequent line
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Long-term use of bevacizumab for the treatment of age-related macular degeneration: safety
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Turoctocog alfa - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Neratinib for HER2-positive early breast cancer
2014	Norwegian Knowledge Centre for the Health Services (NOKC)	[End-of-life care - how to find the appropriate level and intensity of medical treatment of seriously ill and dying patients]
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Methylene blue for the prevention and treatment of ifosfamide-induced encephalopathy: clinical effectiveness and safety
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sofosbuvir - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	Penn Medicine Center for Evidence-based Practice (CEP)	Blood count and coagulation testing before renal biopsy
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Niraparib for high grade serous, platinum sensitive ovarian cancer – second line maintenance therapy
2014	Agency for Healthcare Research and Quality (AHRQ)	Negative pressure wound therapy technologies for chronic wound care in the home setting
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Nasogastric feeding tubes versus percutaneous endoscopic gastrostomy for patients with head or neck cancer: a review of clinical effectiveness and guidelines
2014	Blue Cross Blue Shield Association (BCBS)	Special report: medication adherence
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dapagliflozin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	Penn Medicine Center for Evidence-based Practice (CEP)	Separate instrument sets for prevention of tumor seeding during tumor resection and flap surgery
2014	NIHR Horizon Scanning Centre (NIHR HSC)	Vemurafenib and cobimetinib for previously untreated BRAFV600-mutation positive, unresectable, locally advanced or metastatic melanoma – first line
2014	Agency for Healthcare Research and Quality (AHRQ)	Behavioral sexual risk reduction counseling in primary care to prevent sexually transmitted infections: an updated systematic evidence review for the U.S. Preventive Services Task Force
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Thrombophilia testing for women who have had pregnancy loss: clinical evidence, cost-effectiveness, and guidelines
2014	Blue Cross Blue Shield Association (BCBS)	Bronchial thermoplasty for treatment of inadequately controlled severe asthma
2014	Health Information and Quality Authority (HIQA)	Health technology assessment (HTA) of public access defibrillation
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dolutegravir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]